| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2680 | 2013 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1475 | 2020 |
| European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I S Krege, J Beyer, R Souchon, P Albers, W Albrecht, F Algaba, M Bamberg, ... European urology 53 (3), 478-496, 2008 | 786 | 2008 |
| BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European … S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ... Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011 | 758 | 2011 |
| Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score J Hasford, M Baccarani, V Hoffmann, J Guilhot, S Saussele, G Rosti, ... Blood, The Journal of the American Society of Hematology 118 (3), 686-692, 2011 | 682 | 2011 |
| Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ... Clinical Cancer Research 12 (24), 7374-7379, 2006 | 659 | 2006 |
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow … HM Kantarjian, A Hochhaus, G Saglio, C De Souza, IW Flinn, L Stenke, ... The lancet oncology 12 (9), 841-851, 2011 | 646 | 2011 |
| European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, ... Leukemia 30 (8), 1648-1671, 2016 | 538 | 2016 |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression … S Soverini, G Martinelli, G Rosti, S Bassi, M Amabile, A Poerio, B Giannini, ... Journal of clinical oncology 23 (18), 4100-4109, 2005 | 487 | 2005 |
| The effects of imatinib on pregnancy outcome SM Pye, J Cortes, P Ault, A Hatfield, H Kantarjian, R Pilot, G Rosti, ... Blood, The Journal of the American Society of Hematology 111 (12), 5505-5508, 2008 | 474 | 2008 |
| Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders F Bonifazi, A de Vivo, G Rosti, F Guilhot, J Guilhot, E Trabacchi, ... Blood, The Journal of the American Society of Hematology 98 (10), 3074-3081, 2001 | 444 | 2001 |
| Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Hochhaus, S Saussele, G Rosti, FX Mahon, JJWM Janssen, ... Annals of Oncology 28, iv41-iv51, 2017 | 434 | 2017 |
| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia MS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ... Cancer cell 26 (3), 428-442, 2014 | 373 | 2014 |
| Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy A Paccagnella, M Morello, MC Da Mosto, C Baruffi, ML Marcon, A Gava, ... Supportive care in cancer 18, 837-845, 2010 | 370 | 2010 |
| Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ... Annals of oncology 24 (4), 878-888, 2013 | 329 | 2013 |
| Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population F Efficace, M Baccarani, M Breccia, G Alimena, G Rosti, F Cottone, ... Blood, The Journal of the American Society of Hematology 118 (17), 4554-4560, 2011 | 325 | 2011 |
| Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib TP Hughes, G Saglio, HM Kantarjian, F Guilhot, D Niederwieser, G Rosti, ... Blood, The Journal of the American Society of Hematology 123 (9), 1353-1360, 2014 | 314 | 2014 |
| Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy International Prognostic Factors Study Group Journal of Clinical Oncology 28 (33), 4906-4911, 2010 | 308 | 2010 |
| Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib TD Kim, D Rea, M Schwarz, P Grille, FE Nicolini, G Rosti, L Levato, ... Leukemia 27 (6), 1316-1321, 2013 | 297 | 2013 |
| Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ... Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009 | 293 | 2009 |
